Use of the oxygen gradient ektacytometry in the dose titration of hydroxyurea therapy in children with sickle cell disease
- PMID: 38105480
- DOI: 10.1111/ijlh.14208
Use of the oxygen gradient ektacytometry in the dose titration of hydroxyurea therapy in children with sickle cell disease
References
REFERENCES
-
- Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151. doi:10.1016/S0140-6736(12)61229-X
-
- Hoppe C, Vichinsky E, Quirolo K, Van Warmerdam J, Allen K, Styles L. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol. 2000;22(4):330-334. https://journals.lww.com/jpho-online/Fulltext/2000/07000/Use_of_Hydroxyu...
-
- Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033-1048. doi:10.1001/jama.2014.10517
-
- Rab MAE, van Oirschot BA, Bos J, et al. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. Am J Hematol. 2019;94(February):575-584. doi:10.1002/ajh.25443
-
- Rab MAE, Kanne CK, Bos J, et al. Oxygen gradient ektacytometry derived-biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease. Am J Hematol. 2021;96(1):E29-E32. doi:10.1002/ajh.26031
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
